OncoMatch/Clinical Trials/NCT06437522
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Is NCT06437522 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including BL-B01D1 and PD-1 monoclonal antibody for head and neck squamous cell carcinoma.
Treatment: BL-B01D1 · PD-1 monoclonal antibody — This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) and other solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: antibody-drug conjugate
Exception: with TOP I inhibitors as a toxin
Prior treatment with an ADC drug with TOP I inhibitors as a toxin
Cannot have received: systemic antitumor regimen
Received any previous systemic antitumor regimen for solid tumors such as recurrent or metastatic head and neck squamous cell carcinoma
Cannot have received: immunotherapy
Exception: if developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis
Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis
Cannot have received: anti-tumor treatment
Exception: within four weeks or five half-life before first delivery
Before the first delivery within four weeks or five half-life used anti-tumor treatment
Cannot have received: palliative radiotherapy
Exception: within 2 weeks before the first dose
Palliative radiotherapy was given within 2 weeks before the first dose
Lab requirements
Blood counts
the organ function level must meet the requirements
Kidney function
the organ function level must meet the requirements
Liver function
the organ function level must meet the requirements
the organ function level must meet the requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06437522 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify